Use of nonhuman primate models to develop mucosal AIDS vaccines

Current HIV/AIDS Reports

Volumn 7, Issue 1, 2010, Pages 19-27

  Genescà, Meritxell ^a   Miller, Christopher J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Female genital tract; HIV; Immune activation; SIV

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 15; LENTIVIRUS VECTOR; NEF PROTEIN; PHOSPHORYL LIPID A; RECOMBINANT INTERLEUKIN 15; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HOST-PATHOGEN INTERACTIONS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MUCOUS MEMBRANE; PRIMATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 77249173172     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0035-7     Document Type: Review

References (50)

1. R Steinbrook 2007 One step forward, two steps back: will there ever be an AIDS vaccine? N Engl J Med 357 2653 2655 10.1056/NEJMp0708117 18160684 1:CAS:528:DC%2BD1cXisVOgtQ%3D%3D
2. BD Walker DR Burton 2008 Toward an AIDS vaccine Science 320 760 764 10.1126/science.1152622 18467582 1:CAS:528:DC%2BD1cXlsVGlt7w%3D (Pubitemid 351929619)
3. BF Haynes RJ Shattock 2008 Critical issues in mucosal immunity for HIV-1 vaccine development J Allergy Clin Immunol 122 3 9 10.1016/j.jaci.2008.03.036 18468671 1:CAS:528:DC%2BD1cXotlajt7g%3D
4. •• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 Nov 19 (Epub ahead of print). This article reports the results of the recently completed RV144 phase 3 HIV vaccine trial demonstrating that ALVAC-based HIV vaccines can protect some people from acquiring HIV infection. This result was predicted by preclinical testing of ALVAC-based vaccines in NHP mucosal challenge models [21].
5. P Brandtzaeg H Kiyono R Pabst, et al. 2008 Terminology: nomenclature of mucosa-associated lymphoid tissue Mucosal Immunol 1 31 37 10.1038/mi.2007.9 19079158 1:CAS:528:DC%2BD1cXhtlWhuw%3D%3D
6. J Holmgren C Czerkinsky 2005 Mucosal immunity and vaccines. Nat Med 11 S45 S53 1:CAS:528:DC%2BD2MXjsFWmsro%3D
7. JR McGhee J Xu-Amano CJ Miller, et al. 1994 The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract Reprod Fertil Dev 6 369 379 10.1071/RD9940369 7831485 1:STN:280:DyaK2M7jt1ymsw%3D%3D (Pubitemid 24306946)
8. F Hladik MJ McElrath 2008 Setting the stage: host invasion by HIV Nat Rev Immunol 8 447 457 10.1038/nri2302 18469831 1:CAS:528:DC%2BD1cXmt1Ojtrg%3D (Pubitemid 351735878)
9. CJ Miller Q Li K Abel, et al. 2005 Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus J Virol 79 9217 9227 10.1128/JVI.79.14.9217-9227.2005 15994816 1:CAS:528: DC%2BD2MXmtFOjt70%3D (Pubitemid 40934833)
10. M Stone ZM Ma M Genescà, et al. 2009 Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus Virology 392 260 270 10.1016/j.virol.2009.06.052 19647847 1:CAS:528:DC%2BD1MXhtFajtrnO
11. J Hu MB Gardner CJ Miller 2000 Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells J Virol 74 6087 6095 10.1128/JVI.74.13.6087- 6095.2000 10846092 1:CAS:528:DC%2BD3cXkt1eiu70%3D (Pubitemid 30412980)
12. K Abel DM Rocke B Chohan, et al. 2005 Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection J Virol 79 12164 12172 10.1128/JVI.79.19.12164- 12172.2005 16160143 1:CAS:528:DC%2BD2MXhtVGls7nI (Pubitemid 41346078)
13. BF Keele EE Giorgi JF Salazar-Gonzalez, et al. 2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection Proc Natl Acad Sci U S A 105 7552 7557 10.1073/pnas.0802203105 18490657 (Pubitemid 351830056)
14. • Keele BF, Li H, Learn GH, et al.: Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206:1117-1134. This article identifies key similarities in mucosal transmission and early diversification after mucosal SIV and HIV-1 transmission, validating the biological relevance of the SIV-macaque mucosal transmission model for HIV-1 vaccine and microbicide research.
15. ZM Ma M Stone M Piatak Jr, et al. 2009 High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection J Virol 83 3288 3297 10.1128/JVI.02423-08 19129448 1:CAS:528:DC%2BD1MXjs1WrtLw%3D
16. AJ Hessell P Poignard M Hunter, et al. 2009 Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques Nat Med 15 951 954 10.1038/nm.1974 19525965 1:CAS:528:DC%2BD1MXnt1ShsLs%3D
17. MW Melkus JD Estes A Padgett-Thomas, et al. 2006 Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1 Nat Med 12 1316 1322 10.1038/nm1431 17057712 1:CAS:528:DC%2BD28XhtFKlsLbO (Pubitemid 44706935)
18. PW Denton JD Estes Z Sun, et al. 2008 Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice PLoS Med 5 e16 10.1371/journal.pmed.0050016 18198941 1:CAS:528:DC%2BD1cXmvVSlsbY%3D (Pubitemid 351198263)
19. DM Brainard E Seung N Frahm, et al. 2009 Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice J Virol 83 7305 7321 10.1128/JVI.02207-08 19420076 1:CAS:528:DC%2BD1MXosFKluro%3D
20. C Morgan M Marthas C Miller, et al. 2008 The use of nonhuman primate models in HIV vaccine development PLoS Med 5 e173 10.1371/journal.pmed.0050173 18700814 1:CAS:528:DC%2BD1cXhtlChtrfL
21. KK Van Rompay K Abel JR Lawson, et al. 2005 Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV J Acquir Immune Defic Syndr 38 124 134 10.1097/00126334-200502010-00002 15671796 (Pubitemid 40189318)
22. N Yoshino FX Lu K Fujihashi, et al. 2004 A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates J Immunol 173 6850 6857 15557179 1:CAS:528:DC%2BD2cXhtVShsbzI
23. •• Demberg T, Robert-Guroff M: Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009, 28:20-48. This article includes an extensive review of the mucosal transmission of HIV, the challenges of mucosal immunology, and a detailed summary of the current (2004-2009) approaches to create mucosal immune responses with HIV vaccines.
24. Y Wang LA Bergmeier R Stebbings, et al. 2009 Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells Vaccine 27 870 881 10.1016/j.vaccine.2008.11.084 19084567 1:CAS:528:DC%2BD1MXhtVCntL8%3D
25. P Vagenas VG Williams M Piatak Jr, et al. 2009 Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239 J Acquir Immune Defic Syndr 52 433 442 10.1097/QAI.0b013e3181b880f3 19779309 1:CAS:528:DC%2BD1MXhtlygsLnI
26. SW Barnett IK Srivastava E Kan, et al. 2008 Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope AIDS 22 339 348 10.1097/QAD.0b013e3282f3ca57 18195560 1:CAS:528:DC%2BD1cXlvFWjsg%3D%3D
27. SG Hansen C Vieville N Whizin, et al. 2009 Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge Nat Med 15 293 299 10.1038/nm.1935 19219024 1:CAS:528:DC%2BD1MXhvFKjuro%3D
28. M Genescà PJ Skinner K Bost, et al. 2008 Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys Mucosal Immunol 1 219 228 10.1038/mi.2008.6 19079181 1:CAS:528:DC%2BD1cXksFygurg%3D (Pubitemid 351541307)
29. M Genescà PJ Skinner JJ Hong, et al. 2008 With minimal systemic T-cell expansion, CD8+ T cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus J Virol 82 11181 11196 10.1128/JVI.01433-08 18787003 1:CAS:528:DC%2BD1cXhtlKiu7vN
30. M Genescà MB McChesney CJ Miller 2009 Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6 J Intern Med 265 67 77 10.1111/j.1365-2796.2008.02051.x 19093961 1:CAS:528:DC%2BD1MXhvFCjsL8%3D
31. O Yoshie 2000 Role of chemokines in trafficking of lymphocytes and dendritic cells Int J Hematol 72 399 407 11197204 1:CAS:528: DC%2BD3MXmvF2quw%3D%3D
32. K Kedzierska SM Crowe S Turville, et al. 2003 The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages Rev Med Virol 13 39 56 10.1002/rmv.369 12516061 1:CAS:528: DC%2BD3sXht1eqtrk%3D (Pubitemid 36125504)
33. KF Copeland 2005 Modulation of HIV-1 transcription by cytokines and chemokines Mini Rev Med Chem 5 1093 1101 10.2174/138955705774933383 16375755 1:CAS:528:DC%2BD2MXht1GrurfF
34. M Manrique P Kozlowski SW Wang, et al. 2009 Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination Mucosal Immunol 2 536 550 10.1038/mi.2009.103 19741603 1:CAS:528:DC%2BD1MXht1Krur%2FM
35. M Manrique E Micewicz PA Kozlowski, et al. 2008 DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory AIDS Res Hum Retroviruses 24 505 519 10.1089/aid.2007.0191 18373436 1:CAS:528:DC%2BD1cXjvFKkurk%3D
36. B Falkensammer B Rubner A Hiltgartner, et al. 2009 Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors Retrovirology 6 60 10.1186/1742-4690-6-60 19545395 1:CAS:528: DC%2BD1MXnvVGntLw%3D
37. C Stahl-Hennig M Eisenblatter M Franz, et al. 2007 A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum Front Biosci 12 2107 2123 10.2741/2215 17127448 1:CAS:528:DC%2BD28Xht1WgsbnF
38. WM Bogers D Davis I Baak, et al. 2008 Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge Virology 382 217 225 10.1016/j.virol.2008.09.016 18947849 1:CAS:528:DC%2BD1cXhsVGhu7bK
39. R Hidajat P Xiao Q Zhou, et al. 2009 Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques J Virol 83 791 801 10.1128/JVI.01672-08 18971271 1:CAS:528:DC%2BD1MXotlCmtrk%3D
40. T Demberg JD Boyer N Malkevich, et al. 2008 Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge J Virol 82 10911 10921 10.1128/JVI.01129-08 18753198 1:CAS:528:DC%2BD1cXhtlWiur%2FF (Pubitemid 352691169)
41. Q Zhou R Hidajat B Peng, et al. 2007 Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251) Vaccine 25 8021 8035 10.1016/j.vaccine.2007.09.017 17935840 1:CAS:528:DC%2BD2sXht1amt7vE (Pubitemid 47632993)
42. N Stolte-Leeb K Bieler J Kostler, et al. 2008 Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone Viral Immunol 21 235 246 10.1089/vim.2007.0103 18476770 1:CAS:528:DC%2BD1cXnsVCms7w%3D (Pubitemid 351873368)
43. AS Beignon K Mollier C Liard, et al. 2009 Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques J Virol 83 10963 10974 10.1128/JVI.01284-09 19706700 1:CAS:528:DC%2BD1MXhsVSmt7bF
44. J Zhao L Lai RR Amara, et al. 2009 Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia J Virol 83 4102 4111 10.1128/JVI.02173-08 19224993 1:CAS:528:DC%2BD1MXlt1KqtLk%3D
45. YS Suh KS Park U Sauermann, et al. 2008 Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase Vaccine 26 6690 6698 10.1016/j.vaccine.2008.07.055 18694796 1:CAS:528:DC%2BD1MXhsVanu7Y%3D
46. EE Sparger RA Dubie BL Shacklett, et al. 2008 Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine Virology 374 261 272 10.1016/j.virol.2008.01.020 18261756 1:CAS:528: DC%2BD1cXlslWmsr0%3D
47. RA Dubie S Maksaereekul BL Shacklett, et al. 2009 Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251 Virology 386 109 121 10.1016/j.virol.2009.01.007 19193388 1:CAS:528:DC%2BD1MXjt1amtrg%3D
48. L Lai D Vodros PA Kozlowski, et al. 2007 GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine Virology 369 153 167 10.1016/j.virol.2007.07.017 17698160 1:CAS:528:DC%2BD2sXht1KrsrzL (Pubitemid 350030833)
49. AD Cristillo J Lisziewicz L He, et al. 2007 HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3 Virology 366 197 211 10.1016/j.virol.2007.04.012 17499328 1:CAS:528:DC%2BD2sXpvFGqt74%3D (Pubitemid 47314400)
50. M Vaccari A Boasso ZM Ma, et al. 2008 CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection Mucosal Immunol 1 497 507 10.1038/mi.2008.60 19079217 1:CAS:528:DC%2BD1cXht1CmsLzJ